OmniAb Reports Significant 2025 Revenue Decline and Increased Loss, Projects 2026 Revenue Growth
Summary
OmniAb, Inc. announced a significant 29% revenue decline and increased net loss for the full year 2025, but provided 2026 guidance projecting revenue growth and continued cash burn.
Key Events
-
Full Year 2025 Financial Results
Revenue for 2025 decreased 29% year-over-year to $18.7 million, and the net loss increased to $64.8 million, or $0.57 per share.
-
Fourth Quarter 2025 Performance
Q4 2025 revenue declined 22% to $8.4 million compared to Q4 2024, with a net loss of $14.2 million, or $0.11 per share.
-
2026 Financial Guidance
OmniAb expects 2026 revenue to be in the range of $25 million to $30 million, and projects to end the year with cash and cash equivalents between $30 million and $35 million.
-
Strategic Business Updates
The company launched OmniUltra™, a new transgenic chicken technology, and reported 107 active partners and 407 active programs as of December 31, 2025.
Analysis
OmniAb, Inc. reported a substantial 29% year-over-year revenue decrease for the full year 2025, reaching $18.7 million, alongside an increased net loss of $64.8 million. Fourth-quarter results mirrored this trend with a 22% revenue decline and a higher net loss. This poor performance is a significant negative signal regarding the company's recent operational execution. However, the company provided 2026 revenue guidance of $25 million to $30 million, indicating an expected recovery and growth from the 2025 figures. The projected year-end cash balance of $30 million to $35 million suggests continued cash burn, but the company maintains a runway. Investors should monitor the execution of the 2026 guidance and the impact of new initiatives like OmniUltra™ and partner program advancements on future revenue and profitability.
At the time of this filing, OABI was trading at $1.75 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $260.6M. The 52-week trading range was $1.22 to $3.46. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.